| Utah Cancer Specialists |
| Last Updated November 1, 2019 |
| Protocol Number | Indication | Protocol | NCT number |
| STA004 | Advanced Solid Tumor | A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of a Drug in Patients with Advanced Solid Tumors. | NCT03416816 |
| STA002 | Advanced Solid Tumor | A Phase 1 Study For Study Participants With BRAFF V-600 Mutation In Melanoma Or Other Solid Tumors | NCT03864042 |
| #BRE004 | Breast | A Phase 1a/1b Study of an Antibody, in Patients with Advanced Solid Tumors | NCT03514121 |
| BRE005 | Breast | A Phase 3 Open-Label, Randomized, Study of a Drug versus Treatment of Physician’s Choice in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated | NCT02915744 |
| BRE006 | Breast | A phase 3, Randomized, Open-Label Trial to Evaluate Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer | NCT03701334 |
| BRE007 | Breast | A phase II trial to compare efficacy of Study Drug in combination with Everolimus and Exemestane versus Everolimus and Exemestane in Post-Menopausal Women with HR+ / HER2- Metastatic Breast Cancer | NCT03659136 |
| BRE008 | Breast | A Phase 3 Randomized, Open-Label, Active – Controlled, Multicenter Trial Emerald Study Drug VS. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy | NCT03778931 |
| BRE009 | Breast | A Phase III Randomised Study Assessing the Efficacy and Safety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer | NCT03997123 |
| BRE010 | Breast | A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer | NCT03961698 |
| #ENDO001 | Endometrial | A Phase 1a/1b Study of an Antibody, in Patients with Advanced Solid Tumors | NCT03514121 |
| GAS001 | Gastric | A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating a drug in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer | NCT03694522 |
| LUN002 | Lung NSCLC | A Randomized, Double-Blind, Phase 3 Study of chemptherapy with or without a drug in EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT03515837 |
| LUN003 | Lung NSCLC | A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of a Drug + Standard Therapy + a Study Drug with or without a drug as First-lineTreatment in Participants with Metastatic Nonsquamous NSCLC | NCT03829319 |
| LYM003 | Lymphoma | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Drug in Combination with Standard Therapy in Patients with Relapsed Indolent B-Cell con-Hodgkin’s Lymphoma (iNHL). | NCT02367040 |
| MDS001 | MDS Low Risk | A Phase3,Open-Label,Randomized Study to Compare the Efficiency and Safety of Luspatercept versus Epoetin ALFA for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions | NCT03682536 |
| MM001 | Multiple Myeloma | A Phase 2 Study to Evaluate Subcutaneous Study Drug in Combination with Standard Multiple Myeloma Treatment Regimens | NCT03412565 |
| #OVA004 | Ovarian | A Phase 1a/1b Study of an Antibody, in Patients with Previously Treated Ovarian Cancer | NCT03514121 |
| OVA005 | Ovarian | A Randomized, Double-Blind, Phase 3 Study Comparison of Platinum-Based Therapy with Two Drugs Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III of IV Nonmucinous Epithelial Ovarian Cancer | NCT03602859 |
| PRO002 | Prostate | A Phase 1b-2 Study of a Drug in Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | NCT03431350 |
| PRO003 | Prostate | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer | NCT03748641 |
| REN001 | Renal | A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Renal Cell Carcinoma | NCT03961698 |
